Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Decera Clinical Education Infectious Disease Podcast

Answering the Questions on Which HIV PrEP for Which Patient: Latesha Elopre and Jason Farley

03 Jul 2023

Description

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:How long someone can receive PrEP and the monitoring that is needed over timeRecommendations for monitoring bone health while receiving oral PrEPTreatment as prevention and PrEP efficacy data and options for people who inject drugsThe role of circumcision in HIV preventionThe use of PrEP in pregnancyConcern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP optionsThe possibility of using FTC/TAF on demandInequities in adherence and persistenceCost considerations with different PrEP modalitiesRecommendations for hospitalized patients receiving PrEPPrEP considerations for patients with renal dysfunction and higher BMIsPrEP efficacy based on site of exposurePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaJason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, MarylandLink to full program:https://bit.ly/3Fqdgs9 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.